KYTX

+ Watchlist + Portfolio

Kyverna Therapeutics, Inc.

Regulated industry Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $6.52
52-Week Range: $5.30 – $13.67
Market Cap: $384.67M
P/E (TTM): —
EPS (TTM): -2.93
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.31
PEG Ratio: —
Return on Equity: -87.24%
Return on Assets: -44.51%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 9.06
Debt/Equity: 0.20
Total Debt: $33.00M
Free Cash Flow: $-107.68M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $218.24M

KYTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$7.03M	$0.00	$0.00	$0.00
Research & Development	$28.40M	$49.92M	$112.47M	$133.72M
Selling, General & Admin	$8.01M	$12.48M	$30.13M	$36.11M
Operating Expenses	$36.41M	$62.41M	$142.60M	$169.83M
Operating Income	-$29.38M	-$62.41M	-$142.60M	-$169.83M
EBITDA	-$27.78M	-$58.47M	-$125.20M	-$159.02M
Pretax Income	-$28.89M	-$60.37M	-$127.48M	-$161.31M
Net Income	-$28.89M	-$60.37M	-$127.48M	-$161.31M
Diluted EPS	-1.12	-1.48	-3.33	-3.64
Diluted Shares	25.80M	40.82M	38.33M	44.26M

KYTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$37.73M	$34.65M	$96.62M	$124.09M
Current Assets	$53.25M	$60.66M	$290.60M	$282.95M
Total Assets	$66.92M	$75.19M	$304.64M	$293.83M
Current Liabilities	$11.95M	$19.86M	$33.76M	$36.49M
Long-Term Debt	—	—	—	$24.74M
Total Debt	$10.56M	$9.08M	$8.24M	$29.03M
Total Liabilities	$140.92M	$206.59M	$38.06M	$61.55M
Retained Earnings	-$75.68M	-$136.04M	-$263.52M	-$424.83M
Shareholders' Equity	-$74.00M	-$131.40M	$266.59M	$232.28M
Working Capital	$41.30M	$40.80M	$256.85M	$246.47M

KYTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$36.11M	-$52.41M	-$114.25M	-$153.71M
Capital Expenditure	-$768.00K	-$621.00K	-$2.21M	-$1.13M
Free Cash Flow	-$36.88M	-$53.03M	-$116.45M	-$154.84M
Depreciation & Amortisation	$1.05M	$1.71M	$2.13M	$1.80M
Stock-Based Compensation	$929.00K	$2.22M	$8.36M	$10.08M
Investing Cash Flow	-$14.10M	-$8.79M	-$160.90M	$40.02M
Financing Cash Flow	$11.88M	$58.12M	$337.11M	$141.17M
Net Change in Cash	-$38.33M	-$3.08M	$61.96M	$27.47M

KYTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$37.43M	$35.82M	$30.46M	$30.01M	$30.07M	$24.79M
Selling, General & Admin	$9.97M	$8.59M	$8.27M	$9.27M	$11.29M	$14.77M
Operating Expenses	$47.41M	$44.41M	$38.73M	$39.28M	$41.37M	$39.56M
Operating Income	-$47.41M	-$44.41M	-$38.73M	-$39.28M	-$41.37M	-$39.56M
EBITDA	-$44.11M	-$41.55M	-$36.37M	-$36.99M	-$38.71M	-$37.21M
Pretax Income	-$44.63M	-$42.08M	-$36.79M	-$37.80M	-$39.73M	-$38.32M
Net Income	-$44.63M	-$42.08M	-$36.79M	-$37.80M	-$39.73M	-$38.32M
Diluted EPS	-1.03	-0.97	-0.85	-0.80	-0.66	-0.63
Diluted Shares	43.22M	43.23M	43.42M	47.16M	60.43M	60.90M

KYTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$56.87M	$53.44M	$34.16M	$124.09M	$32.19M	$31.81M
Current Assets	$247.65M	$214.33M	$174.93M	$282.95M	$241.73M	$206.54M
Total Assets	$260.65M	$226.51M	$187.16M	$293.83M	$257.02M	$219.82M
Current Liabilities	$33.29M	$39.79M	$33.87M	$36.49M	$29.67M	$22.80M
Long-Term Debt	—	—	—	$24.74M	$24.81M	$24.88M
Total Debt	$6.94M	$5.92M	$5.02M	$29.03M	$33.76M	$33.00M
Total Liabilities	$36.65M	$42.13M	$35.21M	$61.55M	$61.44M	$54.27M
Retained Earnings	-$308.15M	-$350.24M	-$387.02M	-$424.83M	-$464.56M	-$502.87M
Shareholders' Equity	$224.01M	$184.38M	$151.95M	$232.28M	$195.58M	$165.55M
Working Capital	$214.36M	$174.54M	$141.05M	$246.47M	$212.05M	$183.74M

KYTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$44.91M	-$31.95M	-$43.32M	-$33.53M	-$41.60M	-$40.31M
Capital Expenditure	—	—	-$392.00K	-$537.00K	—	—
Free Cash Flow	-$44.91M	-$32.15M	-$43.71M	-$34.06M	-$41.60M	-$40.85M
Depreciation & Amortisation	$501.00K	$515.00K	$415.00K	$368.00K	$351.00K	$434.00K
Stock-Based Compensation	$2.16M	$2.52M	$2.70M	$2.70M	$3.17M	$3.51M
Investing Cash Flow	$5.58M	$29.17M	$22.56M	-$17.29M	-$50.20M	$36.13M
Financing Cash Flow	-$414.00K	-$649.00K	$1.49M	$140.74M	-$101.00K	$3.79M
Net Change in Cash	-$39.75M	-$3.43M	-$19.28M	$89.93M	-$91.90M	-$388.00K

Market Snapshot

About

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The company's lead product candidate utilizes chimeric antigen receptor (CAR) T-cell technology to selectively deplete B cells that drive autoimmune conditions. Kyverna's pipeline targets diseases such as lupus nephritis, myasthenia gravis, and multiple sclerosis, applying oncology-derived cell therapy approaches to autoimmune disorders.